You just read:

RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer

News provided by

RXi Pharmaceuticals Corporation

Mar 27, 2015, 09:02 ET